Inhibition of Apoptosis in Experimental Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000008
Summary
In glaucoma, the loss of retinal ganglion cells (RGC) proceeds by a mechanism known as apoptosis. Apoptosis is an organized, or programmed, form of cell death that requires the action of a series of proteases (proteins that chop up other proteins) called caspases. In animal models of glaucoma, the protease Caspase-3 is found to be activated in RGCs, where it also cleaves a molecule called amyloid precursor protein (APP). APP is important in Alzheimer’s disease (AD) as well as in glaucoma. In fact, the excessive production of smaller fragments of APP, called amyloid beta, is a hallmark of AD and is thought to be toxic to neurons. Dr. McKinnon is interested in the fact that these two different neurodegenerative diseases, glaucoma and AD, share some key features. He is examining the apoptotic death of RGCs and the possible role of APP in more detail. An understanding of RGC apoptosis could be important in devising protective strategies for preventing glaucomatous damage, and these studies may also illuminate general features of nerve cell death in the central nervous system, making them relevant to other neurodegenerative diseases like AD.
Related Grants
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester